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Metabolic disorders are a relatively uncommon, but important, cause of childhood seizures. Routinely searching for 
a metabolic disorder in epilepsy is usually unrewarding. Children and adolescents with epilepsy can be selected for 
appropriate biochemical investigation by considering the seizure type, age of onset, EEG appearance, family 
history, clinical findings and the results of brain imaging. A limited number of biochemical screening tests can be 
used to categorize the more common metabolic disorders associated with seizures. 
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INTRODUCTION 
Although a large number of biochemical or 
metabolic disorders may be associated with 
seizures, the vast majority of children and 
adolescents with epilepsy do not have any 
demonstrable metabolic abnormality. However, 
it is important to consider the possibility that 
epilepsy may be caused by an underlying metabo- 
lic disorder because of the genetic implications of 
such conditions. Furthermore, the epilepsy and 
any associated neurological dysfunction could be 
resolved with appropriate management of the 
underlying metabolic disturbance. 
Metabolic disorders cause seizures through a 
number of mechanisms’; electrolyte disturbances 
alter the electrical properties of neuronal membr- 
anes; disorders of intermediary metabolism may 
severely disrupt the sources of energy available 
for neuronal function or affect neuro-transmitter 
levels and the abnormal accumulation of in- 
tracellular macromolecules can alter the electrical 
properties of neurones by disrupting the cellular 
membrane which ultimately leads to cell death. 
Each of these mechanisms may be active singly, 
or in varying combinations, in any given metabo- 
lic disorder that causes seizures. 
Performing a routine biochemical ‘screen’ in 
order to detect a possible underlying metabolic 
disorder in all children and adolescents present- 
ing with seizures is usually an unrewarding and 
therefore unnecessary exercise2v3. Instead, a 
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selective approach to the biochemical investiga- 
tion of epilepsy is required and for this the 
clinician needs to know when to suspect an 
underlying metabolic disorder and how to in- 
vestigate and treat the presumed metabolic 
problem. This article will discuss a practical 
approach to the detection of metabolic disorders 
that may cause epilepsy. The treatment of these 
disorders will then be briefly considered. 
When managing epilepsy in childhood, the 
seizure type and, if possible, the epilepsy syn- 
drome should be identified in order to select the 
most appropriate treatment4. Recognition of an 
epilepsy syndrome also increases the accuracy of 
prognosis for an individual’s epilepsy. Epilepsy 
syndromes are defined by the seizure type, age of 
seizure onset, EEG findings and associated 
features such as family history, clinical findings 
and the results of imaging studiessT6. Con- 
veniently, these same categories can also be 
considered when determining the likelihood of an 
underlying metabolic disorder in an infant, child 
or adolescent with epilepsy. 
SEIZURE TYPE 
There is no single seizure type that is invariably 
associated with an underlying disorder of meta- 
bolism. Although myoclonic seizures, particularly 
erratic or fragmentary myoclonic seizures, are 
relatively more common in patients with metabo- 
lic disorders, most children and adolescents who 
0 1997 British Epilepsy Association 
194 J. Gibbs & R.E. Appleton 
exhibit myoclonic seizures do not have a metabo- 
lic disease7. As well as causing ‘non-specific’ 
myoclonic seizures, metabolic diseases are as- 
sociated with a particular group of myoclonic 
epilepsies known as the ‘progressive myoclonus 
epilepsies’ in which frequent and severe myo- 
clonic seizures are usually associated with prog- 
ressive neurological dysfunction that usually 
includes ataxia and dementia’. 
Infantile spasms are not commonly caused by 
metabolic disorders, now that most patients with 
phenylketonuria receive early dietary treatment 
following the introduction of neonatal screening. 
Infantile spasms have occasionally been described 
in infants with pyridoxine dependency, biotini- 
dase deficiency, non-ketotic hyperglycinaemia, 
Leigh’s disease, Alpers’ disease, Menkes disease, 
Krabbe disease and neonatal adrenoleuko- 
dystrophy’. Although myoclonic seizures are 
relatively more common in metabolic disorders, 
any other seizure type can occur. Furthermore, 
severe metabolic derangements might be ex- 
pected to cause global cerebral dysfunction 
resulting in generalized seizures, but in fact 
partial seizure are not uncommon’“*‘l. 
Recognizing epileptic seizures can be particu- 
larly difficult in the neonatal period and this 
applies equally to seizures associated with meta- 
bolic disturbances. For example, massive myo- 
clonus and repeated, brief tonic-clonic seizures in 
an infant with biotinidase deficiency”, and some 
of the erratic, massive myoclonic jerks in several 
infants with non-ketotic hyperglycinaemia’3, were 
shown to be non-epileptic on detailed neurophy- 
siological investigation. 
AGE OF ONSET 
There are a large number of metabolic disorders 
that affect the nervous system in the neonatal 
period14, and during later childhoodi5. These 
disorders can be broadly classified according to 
the age of onset of clinical manifestations?. With 
the possible exceptions of pyridoxine depen- 
dency, non-ketotic hyperglycinaemia and sulphite 
oxidase deficiency, metabolic disorders do not 
invariably cause seizures. However, certain meta- 
bolic disorders are typically associated with 
seizures and the usual age of onset of seizures in 
each of these disorders is shown in Table 1. The 
more common disorders appear in bold type. 
Although Table 1 indicates the usual age at which 
seizures commence, for any given metabolic 
disorder a minority of individuals may develop 
seizures outside the age shown, or may in fact 
never experience any seizures. There are many 
other metabolic disorders that can cause seizures 
which are not listed in Table 1, either because 
seizures are only an occasional finding, or because 
seizures occur late in the course of a disease 
which is dominated by other neurological 
features. 
Hypoglycaemia and hypocalcaemia are by far 
the most common metabolic causes of seizures. 
These two biochemical derangements are most 
frequently found early in the neonatal period and 
account for almost 5% of all neonatal seizures17. 
Hypoglycaemia in the neonatal period usually 
results either from glucose insufficiency in small- 
for-gestation, large-for-gestation or low-birth- 
weight infants, or from increased glucose utiliza- 
tion in ill neonates or neonates with hyperinsulin- 
ism. Hypoglycaemia may also be found in 
association with a variety of illnesses throughout 
childhood, particularly in infants and young 
children who are least able to maintain adequate 
blood glucose levels in stressful situations. Less 
commonly, hypoglycaemia may occur secondary 
to other metabolic disorders. Although hypogly- 
caemia may not always be a primary cause of 
seizures, its correction is vital in order to reduce 
the risk of additional neuronal injury from 
continuing seizure activity. 
Hypocalcaemia tends to occur during the first 3 
days of life in low-birth-weight infants and infants 
of diabetic mothers, or later in the neonatal 
period if incorrect quantities of calcium and 
phosphate are given in enteral or parental feeds. 
Severely disordered sodium and water balance 
leading to seizures usually results from conditions 
associated with inappropriate secretion of anti- 
diuretic hormone, or from inappropriate salt and 
water replacement therapy. 
Disorders of intermediary metabolism are most 
likely to present abruptly in the neonatal period, 
although some of these disorders can occur 
episodically during childhood, often in associa- 
tion with infective illnesses, stress (including 
trauma) or, in some cases, following an unusually 
high protein intake. Metabolic storage and 
degenerative disorders tend to develop more 
insidiously later in infancy or during childhood. 
EEG FINDINGS 
There are no specific EEG findings that are 
invariably associated with metabolic diseases. 
Certain EEG appearances are characteristic of 
particular disorders of metabolism but are not 
necessarily exclusive to these disorders. 
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Table 1: Typical age of onset of seizures in metabolic disorders 
Category Disorder 
Electrolyte, Hypoglycaemia 
mineral ions Hypocalcaemia/magnesaemia 
and glucose Hypo/hypernatraemia 
Menkes disease 
Intermediary Pyruvate enzyme deficiencies 
carbohydrate Mitochondrial resp. chain disorders 
metabolism Glycogen storage, type 1 
Intermediary Maple syrup urine disease 
protein Phenylketonuria 
metabolism Urea cycle disorders 
Pyridoxine dependency 
Non-ketotic hyperglycinaemia 
Sulphite oxidase deficiency 
Fatty acid oxidation disorders Intermediary fat 
metabolism 
Intermediary fat, 
carbo., protein 
metabolism 
Purine metabolism Lesch-Nyhan syndrome + 
Metabolic Tay Sachs/Sandoff disease (+) + 
storage Niemann-Pick disease, type A + 
disorder Infantile Gaucher + 
Krabbe disease + 
Juvenile Gaucher + 
Neuronal ceroid lipofuscinosis + 
Juvenile GM2 gangliosidosis + 
Sanfillipo disease + 
Sialidosis type 1 + 
Lafora disease + 
Presumed metab. Progressive neuronal degen. (+I + 
degenerative of childhood + liver disease 
disorder (Alper’s disease) 
The more common disorders associated with seizures are indicated in bold. 
Carbo.: carbohydrate; metab.: metabolism. 
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Age of seizure onset 
Neonatal Infancy Childhood 
+ (+I (+I 
+ 
+ (+I 
+ 
;+I 
(+I 
+ + 
+ 
+ (+I 
+ ;+I (+I 
+ (+I 
+ 
+ 
+ . (+) 
Organic acidaemias + (+I (+I 
Peroxisomal disorders + 
The EEG in infants with non-ketotic hyper- 
glycinaemia shows a burst suppression pattern 
where intermittent bursts of high voltage activity 
alternate with periods of little or no background 
electrical activity13. This may present in the 
neonatal period (early myoclonic en- 
cephalopathy) or during infancy (early infantile 
epileptic encephalopathy, or Ohtahara syn- 
drome). Unusual 4-5 Hz bursts of comb-like 
activity may be seen in the EEG in maple syrup 
urine disease”, while in pyridoxine dependency 
synchronous l-4 Hz bilateral high voltage sharp 
and slow wave activity disappears following 
intravenous pyridoxine”. An ‘hypsarrhythmic- 
like’ EEG may be seen in pyridoxine dependency 
and because of this some clinicians recommend 
giving intravenous pyridoxine to all infants who 
present with newly diagnosed infantile spasms, 
during their initial EEG; however, using this 
protocol, the positive identification of genuine 
pyridoxine dependency would appear to be 
extremely low (personal data and 
communications). 
The neuronal ceroid lipofuscinoses comprises a 
group of lipopigment storage diseases with a 
presumed metabolic basis. The EEG findings 
contribute towards the identification of the 
different disease groups, with the most striking 
appearance occurring in the late infantile form of 
the disease where low-rate photic stimulation 
(usually at one flash per second) produces a large 
amplitude response, similar to the appearance of 
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a visual evoked potential*‘. A variety of EEG 
changes may be found in mitochondrial disorders 
but, as the disease progresses, the EEG in most 
subjects eventually shows a marked slowing of the 
background alpha rhythm*‘. 
A number of metabolic disturbances have been 
reported in progressive neuronal degeneration of 
childhood with liver disease (Alpers’ disease), 
including mitochondrial disorders**. Once se- 
izures becme established in this disorder, the 
EEG frequently comprises very slow (4 Hz), 
high amplitude activity with superimposed low 
amplitude polyspikes23, which may be focal or 
generalized. This activity (which is not specific for 
Alpers’ disease) is often termed ‘PLEDs’ (peri- 
odic lateralizing epileptiform discharges). 
FAMILY HISTORY 
Parental consanguinity increases the risk of an 
inborn error of metabolism since most are 
recessively inherited. In contrast, mitochondria 
are maternally inherited, and so when epilepsy, 
especially myoclonic epilepsy, appears to be 
transmitted through the female side of a family 
then a mitochondrial disorder may be responsible 
for the seizures. The currently identified mitoch- 
ondrial disorders which are particularly as- 
sociated with seizures include ‘MERRF’ [myo- 
clonic epilepsy with ragged red fibres (seen on 
muscle biopsy)] and ‘MELAS’ (mitochondrial 
encephalopathy, lactic acidosis and stroke-like 
episodes). Finally, an underlying metabolic dis- 
order should be considered in any child with 
7 epilepsy who has a sibling that suffered an 
unexplained death. 
CLINICAL FINDINGS 
This section summarizes the salient clinical 
features of disorders of intermediary metabolism, 
metabolic storage diseases and metabolic, or 
presumed metabolic, degenerative diseases that 
typically produce seizures. More detailed ac- 
counts of these disorders may be found in 
standard reference texts24-29. 
Neonates with hypoglycaemia or hyper- 
calcaemia are often excessively jittery, and those 
with Menkes’ disease have characteristic friable 
and twisted strands of hair (pili torti). Disorders 
of intermediary metabolism presenting in the 
neonatal period or in early infancy usually have 
an acute onset with varying combinations of 
seizures, decreased consciousness, hypotonia, 
vomiting and respiratory difficulties. Variants of 
these same disorders of intermediary metabolism 
may present episodically during childhood with 
similar features, together with ataxia, particularly 
during fasting, follwing an excessive protein 
intake, or in protein catabolic states (including 
infections and following trauma or surgery). 
However, these clinical features may also be 
found in a number of epilepsies during periods 
when seizures are poorly controlled, even when 
there is no underlying metabolic or degenerative 
disease. 
Seizures occurring in subjects with metabolic 
storages disorders form part of a gradually 
evolving clinical picture in which neurological 
findings may include developmental regression, 
hypotonia or hypertonia, dystonia, ataxia and 
retinal degeneration. General non-neurological 
features may also be present, such as failure to 
thrive, hepatosplenomegaly and cardiomyopathy. 
Although disorders of intermediary metabol- 
ism tend to present either acutely or episodically 
with encephalopathy and seizures, and metabolic 
storage or degenerative disorders tend to present 
with more gradual neurological dysfunction, this 
distinction is not absolute. The mitochondrial 
respiratory chain diseases may present, like other 
disorders of intermediary metabolism, with se- 
izures, severe acidosis and encephalopathy par- 
ticularly at times of stress; Leigh’s syndrome may 
often present in this manner and should therefore 
be considered. However, mitochondrial disorders 
may also present with progressive neurological 
features such as ophthalmoplegia, retinal 
dystrophy (e.g. Kearns-Sayre syndrome), sen- 
sorineural deafness, ataxia and a peripheral 
neuropathy (e.g. ‘NARP’-neuropathy, ataxia, 
retinitis pigmentosa) or myopathy as well as with 
non-neurological signs including failure to thrive, 
short stature3’ or bone marrow failure (e.g. 
Pearson’s syndrome). 
Dysmorphic features may occasionally be 
found in children with metabolic disorders. Some 
infants with pyruvate dehydrogenase deficiency 
have frontal bossing, a wide nasal bridge, and 
flared nostrils and subsequently develop 
microcephalf’. Infants with Zellweger syndrome 
have wide fontanelles and cranial sutures, with 
high foreheads and flattening of the occiput and 
supraorbital ridges3*, while neonates with sulphite 
oxidase deficiency may show coarse facial fea- 
tures with a wide nasal bridge, large ears and 
enophthalmos33. 
BRAIN IMAGING 
Brain imaging sometimes reveals extensive ab- 
normalities in the white or grey matter during 
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acute encephalopathies caused by disorders of 
intermediary metabolism such as cerebral oed- 
ema, destructive lesions and disorders of myeli- 
nation. A number of biochemical disorders may 
present with seizures in children who may or may 
not show additional neurological problems, in- 
cluding developmental delay, in whom neuroima- 
ging may suggest an underlying aetiology; these 
include Canavan’s disease (increased N- 
acetylaspartic acid in urine and plasma), 
Alexander’s disease (no biochemical abnormality 
as yet identified) and severe, childhood-onset 
adrenoleucodystrophy (increased levels of very 
long chain fatty acids in plasma and cultured skin 
fibroblasts). Cerebral calcification, readily dem- 
onstrated on computerized tomography (CT) but 
far less well shown on magnetic resonance 
imaging (MRI) may also provide aetiological 
clues including coeliac disease (predominantly 
involving the occipital cortex) and parathyroid 
dysfunction, a mitochondrial cytopathy and de- 
ficiencies of biotinidase and biopterins (primarily 
involving the basal ganglia). Importantly, certain 
structural abnormalites may also be found in 
subjects with metabolic disorders; specifically 
agenesis or hypoplasia of the corpus collosum, 
sometimes in association with other brain malfor- 
mations, has been described in non-ketotic 
hyperglycinaemia, Zellweger syndrome, his- 
tidinaemia, pyruvate carboxylase deficiency and 
pyruvate dehydrogenase deficiency4. Localized 
thinning of the corpus collosum and a veriety of 
other cerebral malformations have also been 
noted in early onset pyridoxine dependency35. 
These brain malformations and the dysmorphic 
features described earlier indicate the adverse 
effect of some metabolic disorders on foetal 
development, and have obvious implications for 
the investigation of children with seizures who are 
found to have cerebral dysgenesis, particularly if 
it involves the corpus callosum. If the child’s 
overall clinical (includinng the neurological) 
status cannot be explained solely by dysgenesis of 
the corpus callosum, then an underlying metabo- 
lic abnormality should be considered, and sought. 
BIOCHEMICAL INVESTIGATIONS 
Blood glucose, calcium and magnesium should be 
checked in all children and adolescents with 
seizures in whom a metabolic disorder is sus- 
pected. The investigation and management of the 
less common disorders of metabolism that may be 
associated with epilepsy requires liaison with staff 
at a reference biochemistry laboratory, a paediat- 
rician with an interest in metabolic disorders and 
a paediatric neurologist. Several useful schemes 
for investigating metabolic disorders have been 
published1*14*36,37. In patients presenting with an 
acute encephalopathy associated with seizures it 
should be possible to categorize broadly any 
underlying disorder of intermediary metabolism 
using a few ‘screening’ biochemical investigations 
which will be available in most hospitals as shown 
(Table 2), however, these screening tests will all 
be negative in a few disorders as indicated at the 
end of Table 2. 
Further biochemical investigation will be re- 
quired to help diagnose the specific intermediary 
metabolic disorder which usually includes measu- 
rement of blood, urine and CSF amino acids, 
urine organic acids, blood and CSF 
lactate/pyruvate levels and very long chain fatty 
acids in the blood. It is important to obtain CSF 
because in certain metabolic disorders the bioch- 
emical abnormality may be confined to the CSF, 
as in some of the mitochondrial disorders or in 
late-presenting non-ketotic hyperglycinaemia, or 
because the ratio of CSF to blood metabolites 
Table 2: Preliminary biochemical investigation of suspected disorders of intermediary metabolism 
Acidosis Hypo-glycaemia Ketonuria fLactate 
(blood) (blood) 
mmonia 
;b?ood) 
Maple syrup 
urine disease 
Organic acidaemia 
Fatty acid 
oxidation disorder 
Lactic acidosis 
Urea cycle disorder 
Non-ketotic 
hyperglycinaemia, 
Peroxisomal disorder 
+ (+) + 
+ + + (+I 
(+I + + 
+ (+I + 
+ 
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could be diagnostic. This is particularly relevant 
for mitochondrial disorders including Leigh’s 
syndrome where the CSF levels of lactate may be 
markedly elevated despite normal levels in the 
plasma; this phenomenon may also be seen 
between blood and other tissues, including 
muscle. The phenomenon is explained by mitoch- 
rondial DNA heteroplasmy in which different 
levels of mutant mitochondrial DNA are ex- 
pressed in different tissues (and body fluids) from 
the same patient. 
In the more slowly progressive metabolic 
storage and degnerative diseases, tbe general 
nature of the disorder, and the investigations 
required, are often suggested by a careful history 
and clinical examination38*39. Many of these 
disorders can be confirmed from the reduced or 
absent activity of the relevant enzyme measured 
in white blood cells in a supra-regional labora- 
tory. Abnormal storage material may produce a 
characteristic histological appearance which will 
be readily identified on biopsy of the skin, rectum 
or conjunctiva. Tissue biopsies may atso be 
required in certain disorders of intermediary 
metabolism, for example pyruvate enzyme ac- 
tivities can be measured in fibroblasts obtained 
from a skin biopsy, and individual mitochondrial 
respiratory chain enzymes can be assayed, and 
mitocbondrial morphology examined, in a muscle 
biopsy sample3’. 
MANAGEMENT 
The detailed management of metabolic disorders 
can be found in the standard texts previously 
quoted. In general, when patients present acutely 
with seizures in association with an en- 
cephalopathic illness, due to a disorder of 
intermediary metabolism, then initial manage- 
ment should be aimed at securing the airway and 
maintaining adequate respiration and tissue per- 
fusion. A rapid bed-side blood glucose measure- 
ment must be obtained. Continuing seizures 
require urgent antiepileptic drug treatment ac- 
cording to the specific clinical situation and local 
protocol. If an underlying metabolic disorder is 
suspected, further biochemical investigations 
need to be undertaken as previously discussed. 
Peritoneal dialysis, haemodialysis, haemofiltra- 
tion or exchange transfusion may be required for 
severe metabolic acidosis not responding readily 
to intravenous infusions of sodium bicarbonate, 
or for severe hyperammonaemia. The long-term 
management of amino acidaemias usually re- 
quires the dietary restriction of certain amino 
acids, and low protein diets are required in the 
organic acidaemias and urea cycle disorders. 
Prolonged fasting should also be avoided in those 
children who are at risk from developing hyp- 
oglycaemia. Specific dietary supplements may be 
helpful, either to provide substrates to facilitate 
alternative metabolic pathways, or to enhance 
any residual enzyme activity through the ad- 
ministration of high doses of vitamin cofactors, as 
with thiamine, riboflavine, pyridoxine and vitam- 
ins C and K for some of the mitochondrial 
cytopathies; however, it must be emphasized that 
the use of these therapies is essentially empirical 
and their effectiveness largely unproven, although 
anecdotal (i.e. single case) reports have oc- 
casionally suggested some benefit. 
There is no consistently effective treatment 
currently available for metabolic storage dis- 
orders. Direct replacement of deficient enzymes 
has been attempted by means of regular intravas- 
cular infusions of the appropriate enzyme and 
direct gene replacement has been attempted 
using viral vectors, but with little clinical benefit. 
Replacement of both the defective enzyme and 
the respective gene is possible using leucocyte 
intravascular infusions or bone marrow transpl- 
antation. The clinical response following bone 
marrow transplantation in storage disorders, once 
neurological signs are established, has been 
generally disappointing4’. More encouraging re- 
sults may be seen if transplantation is undertaken 
early in the disease process when the child is 
asymptomatic but shows abnormalities only on 
psychological testing or neuroimaging, as is 
currently ‘recommended’ in severe, childhood- 
onset adrenoleucodystrophy41. None of these 
treatments directly address the enzyme deficiency 
within the central nervous system but there is 
hope from animal studies that treating transpl- 
anted bone marrow to massively increase produc- 
tion of the deficient enzyme and to encourage 
infiltration of these cells into the brain may 
substantially improve the treatment of lysosomal 
storage disorders4*. 
Recurrent seizures occurring in children and 
adolescents with an underlying metabolic dis- 
order may resolve if the metabolic disorder can 
be corrected, but otherwise the seizures should be 
treated with standard antiepileptic drugs. Caution 
is required when considering the use of phenytoin 
and particularly valproate in young children with 
multiple seizure types (particularly myoclonic 
seizures), in association with developmental delay 
and suspected disorders of metabolism because of 
the risk of hepatic necrosis which might, at least 
in some cases, be due to an inherited metabolic 
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disorder4M5, which could be ‘unmasked’ by these 
drugs. Low levels of plasma carnitine have been 
documented in some patients with epilepsy 
receiving sodium valporate/valporic acid; in view 
of this administration of L-carnitine has been 
advocated for children with apparent ‘valproate- 
associated hepatotoxicity’, and although this has 
resulted in an increase in plasma levels of 
free-carnitine, this has not been a consistent 
finding. In addition, it remains unclear as to 
whether this biochemical ‘improvement’ is as- 
sociated with any significant clinical improvement 
in the hepatic or overall neurological status of the 
child, or whether the use of carnitine could 
actually prevent the hepatotoxicity of sodium 
valproate46. 
In conclusion, metabolic disorders are a rela- 
tively uncommon, but important, cause of child- 
hood seizures. Routinely searching for a metabolic 
disorder, other than hypoglycaemia, in children 
and adolescents with epilepsy is generally unre- 
warding. Instead, biochemical investigations 
should be reserved for those subjects with 
epilepsy in whom a metabolic disorder is sus- 
pected on considering the seizure type, age of 
onset, EEG appearance, family history, clinical 
findings and results of any brain imaging studies. 
Of these various features, the age of onset, 
seizure type (usually, but not invariably, myoc- 
ionic seizures) and the clinical findings are often 
the most helpful in determining the probability of 
an underlying metabolic disorder. A few, readily 
available, biochemical screening tests can broadly 
categorize the more common metabolic disorders 
associated with seizures. Further biochemical 
investigation and management of the suspected 
metabolic disorder should be undertaken in 
consultation with those who have experience of 
such disorders. 
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